Disopyramide indications and usage: Difference between revisions
Created page with "__NOTOC__ {{Disopyramide}} {{CMG}}; {{AE}} {{SS}} ==Indications and Usage== <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = NORPACE (DISOPYR..." |
No edit summary |
||
| Line 5: | Line 5: | ||
==Indications and Usage== | ==Indications and Usage== | ||
Norpace and Norpace CR are indicated for the treatment of documented ventricular [[arrhythmias]], such as sustained ventricular [[tachycardia]], that, in the judgment of the physician, are life-threatening. Because of the proarrhythmic effects of Norpace and Norpace CR, their use with lesser [[arrhythmias]] is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. | |||
Initiation of Norpace or Norpace CR treatment, as with other antiarrhythmic agents used to treat life-threatening [[arrhythmias]], should be carried out in the hospital. Norpace CR should not be used initially if rapid establishment of disopyramide plasma levels is desired. | |||
Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular [[arrhythmias]].<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = NORPACE (DISOPYRAMIDE PHOSPHATE) CAPSULE, GELATIN COATED [G.D. SEARLE LLC DIVISION OF PFIZER INC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e2aa1642-d262-4520-bc6a-9fd3ad795677 | publisher = | date = | accessdate = 3 March 2014 }}</ref> | |||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = NORPACE (DISOPYRAMIDE PHOSPHATE) CAPSULE, GELATIN COATED [G.D. SEARLE LLC DIVISION OF PFIZER INC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e2aa1642-d262-4520-bc6a-9fd3ad795677 | publisher = | date = | accessdate = 3 March 2014 }}</ref> | |||
==References== | ==References== | ||
Revision as of 02:04, 3 March 2014
| Disopyramide |
|---|
| NORPACE® FDA Package Insert |
| Indications and Usage |
| Dosage and Administration |
| Contraindications |
| Warnings and Precautions |
| Adverse Reactions |
| Drug Interactions |
| Use in Specific Populations |
| Overdosage |
| Description |
| Clinical Pharmacology |
| Nonclinical Toxicology |
| How Supplied/Storage and Handling |
| Labels and Packages |
| Clinical Trials on Disopyramide |
| ClinicalTrials.gov |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]
Indications and Usage
Norpace and Norpace CR are indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening. Because of the proarrhythmic effects of Norpace and Norpace CR, their use with lesser arrhythmias is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided.
Initiation of Norpace or Norpace CR treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. Norpace CR should not be used initially if rapid establishment of disopyramide plasma levels is desired.
Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias.[1]
References
- ↑ "NORPACE (DISOPYRAMIDE PHOSPHATE) CAPSULE, GELATIN COATED [G.D. SEARLE LLC DIVISION OF PFIZER INC]". Retrieved 3 March 2014.